Project Details
Description
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or...
| Status | Active |
|---|---|
| Effective start/end date | 5/1/25 → 4/30/36 |
Funding
- ASTRAZENECA
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.